Systemic reaction to omalizumab.
Chipps
Bradley
B
D000085:Acetates / Q000627:therapeutic use; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000368:Aged; D000420:Albuterol / Q000031:analogs & derivatives / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001168:Arthritis / Q000150:complications; D001249:Asthma / Q000150:complications / Q000188:drug therapy; D003521:Cyclopropanes; D003863:Depression / Q000150:complications; D004342:Drug Hypersensitivity / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology*; D004359:Drug Therapy, Combination; D004837:Epinephrine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000150:complications / Q000188:drug therapy; D006973:Hypertension / Q000150:complications; D008775:Methylprednisolone / Q000627:therapeutic use; D000069444:Omalizumab; D011804:Quinolines / Q000627:therapeutic use; D012220:Rhinitis / Q000150:complications / Q000188:drug therapy; D000068299:Salmeterol Xinafoate; D012640:Seizures / Q000139:chemically induced; D013440:Sulfides; D013575:Syncope / Q000139:chemically induced
D000085:Acetates; D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D000069444:Omalizumab; D000068299:Salmeterol Xinafoate; C093875:montelukast; D000420:Albuterol; D008775:Methylprednisolone; D004837:Epinephrine